These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17894090)

  • 1. On the coexistence of parkinsonism and tardive dyskinesia.
    Fann WE; Lake CR
    Dis Nerv Syst; 1974 Jul; 35(7):324-6. PubMed ID: 17894090
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of the novel aminoadamantane derivative A-7 on Parkinsonian syndrome induced by systemic administration of neurotoxin MPTP].
    Nerobkova LN; Val'dman EA; Voronina TA; Markina NV; Sharkova LM
    Eksp Klin Farmakol; 2000; 63(3):3-6. PubMed ID: 10934586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
    Kis B; Hedrich K; Kann M; Schwinger E; Kömpf D; Klein C; Pramstaller PP
    Neurology; 2005 Sep; 65(5):761. PubMed ID: 16157916
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa-induced dyskinesias in spinocerebellar ataxia type 2.
    Ferrara JM; Adam OR; Ondo WG
    Arch Neurol; 2010 Jan; 67(1):114-5. PubMed ID: 20065139
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
    Kapitsa IG; Ivanova EA; Kokshenev II; Nepoklonov AV; Val'dman EA; Voronina TA
    Eksp Klin Farmakol; 2014; 77(5):3-5. PubMed ID: 25033563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portable device for quantifying parkinsonian wrist rigidity.
    Caligiuri MP
    Mov Disord; 1994 Jan; 9(1):57-63. PubMed ID: 7908119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choreiform dyskinesias following levodopa treatment of parkinsonism due to osmotic demyelination syndrome.
    de Souza A; de Souza RJ
    Parkinsonism Relat Disord; 2017 Oct; 43():120-121. PubMed ID: 28729089
    [No Abstract]   [Full Text] [Related]  

  • 9. [The antiparkinson activity of a new adamantane derivative].
    Val'dman EA; Voronina TA; Nerobkova LN
    Eksp Klin Farmakol; 1999; 62(4):3-6. PubMed ID: 10513325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Růzicka E; Urgosík D; Jech R; Roth J; Vymazal J; Mecír P; Vladyka V
    Mov Disord; 2005 Jun; 20(6):759-62. PubMed ID: 15782419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of psychosis in elderly patients with parkinsonism.
    Hasnain M; Vieweg WV; Baron MS; Beatty-Brooks M; Fernandez A; Pandurangi AK
    Am J Med; 2009 Jul; 122(7):614-22. PubMed ID: 19559160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.
    Angus S; Sugars J; Boltezar R; Koskewich S; Schneider NM
    J Clin Psychopharmacol; 1997 Apr; 17(2):88-91. PubMed ID: 10950469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary.
    Fox S
    Mov Disord; 2013 Aug; 28(9):1214-5. PubMed ID: 23857852
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiparkinsonics, neuroleptics, and tardive dyskinesia.
    Mallya A; Jose C; Baig M; Williams R; Cho D; Mehta D; Volavka J
    Biol Psychiatry; 1979 Aug; 14(4):645-9. PubMed ID: 39640
    [No Abstract]   [Full Text] [Related]  

  • 15. Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.
    Pita Lobo P; Coelho M; Mestre TA; Rosa MM; Ferreira JJ
    Mov Disord; 2013 Aug; 28(9):1212-4. PubMed ID: 23861327
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism.
    McGarry A; Biglan K
    Parkinsonism Relat Disord; 2013 Jun; 19(6):643-4. PubMed ID: 23561947
    [No Abstract]   [Full Text] [Related]  

  • 17. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Cenci MA
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-associated Parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy.
    Kobylecki C; Silverdale MA; Varma A; Dick JP; Kellett MW
    Mov Disord; 2009 Dec; 24(16):2441-2. PubMed ID: 19908326
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes].
    Ciuca I; Bulandra R; Serbanesco A; Ninosu N
    Rev Neurol (Paris); 1972 Aug; 127(2):305-8. PubMed ID: 4672049
    [No Abstract]   [Full Text] [Related]  

  • 20. [Present-day treatment of parkinsonism in the aged].
    Siegfried J
    Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.